Emerging Treatment Approaches and Multidisciplinary Management of Unresectable Stage III Non-Small Cell Lung Cancer - Episode 5
Tailoring Chemoradiotherapy Approaches in Unresectable Stage III NSCLC
This segment transitions to discussing the management of unresectable non–small cell lung cancer (NSCLC), focusing on the distinctions between concurrent and sequential chemoradiation. It highlights patient selection, treatment tolerability, the role of advanced radiation technologies, and considerations for minimizing adverse effects while ensuring optimal outcomes.
Video content above is prompted by the following:
- How do you select patients with unresectable stage 3 NSCLC for sequential vs concurrent chemoradiotherapy (cCRT)? How do available data help inform your treatment decision?
- PACIFIC: 5-year follow-up data
- PACIFIC-R
- PACIFIC-6
- How do you manage patients not suitable for cCRT?
Related Content:
